Michal Kubiak is an Oncology physician. OpenAlex indexes 28 publications with 502 citations (h-index 8).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4111 W. Lillian Street Apt. F
Mchenry, IL 60050
Telephone
224-828-0682Provider last certified this registry record 17 Aug 2023.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- Novartis Pharmaceuticals CorporationProgram year20251 payment
- Aveo Pharmaceuticals, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
31.9%Aromatase Inhibitor8%Anastrozole67%Letrozole33%Part D<11 patientsKinase inhibitor7.1%Brukinsa65%Sprycel35%Part D<11 patients+ 5 more classes in this area
Metabolism & gastrointestinal
26.6%Serotonin-3 Receptor Antagonist8.4%Ondansetron Hcl75%Ondansetron Odt25%Part D<11 patientsCorticosteroid7.8%Prednisone100%Part D≥13 patients+ 3 more classes in this area
Dermatology
14.7%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor14.7%Acyclovir100%Part D≥19 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL
Journal of Clinical Oncology
2024 - Real World Outcomes for AYA Patients with Relapsed/Refractory B-Cell ALL Receiving CD19-Directed CAR T-Cell Therapy
Biology of Blood and Marrow Transplantation
2024 - The predictive value of the MASCC score in patients with febrile neutropenia.
Journal of Clinical Oncology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”